Skip to content
DataLookout
Menu

NCT07777211

A Study of GKL-006 Injection in Patients With Advanced Pancreatic Cancer

StatusRecruiting
PhasePhase 1/2
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Enrollment reopened
    • Primary endpoint(s) modified
    • Secondary endpoints: 15 to 36
    • Site details revised
  2. Notable Eligibility criteria expanded, about 28 words
    • Primary endpoints: 2 to 3
    • Secondary endpoints revised (15)
    • Study title shortened, about 2 words
  3. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Phase I: Incidence of Dose-Limiting Toxicities
Timeframe: From the first dose until 42 days
Phase I: Incidence and Severity of Adverse Events and Serious Adverse Events
Timeframe: Up to 18 months
Phase II: Progression-Free Survival (PFS) Assessed by Independent Review Committee (IRC) per RECIST 1.1
Timeframe: Up to 18 months

Secondary (36)

Phase I: Progression-Free Survival
Phase I: Objective Response Rate
Phase I: Disease Control Rate
Phase I: Duration of Response
Phase I: Time to Progression
Show 31 moreShow less
Phase I: One-Year Overall Survival Rate
Phase I: Overall Survival
Phase I: Tumour Markers
Phase I: Quality of Life Change From Baseline Measured by European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Phase I: Pancreatic Cancer-Specific Quality of Life Change From Baseline Measured by the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Pancreatic Cancer Module 26 (EORTC QLQ-PAN26).
Phase I: Fatigue Change From Baseline Measured by the Brief Fatigue Inventory (BFI)
Phase I:Pain Change From Baseline Measured by the Numeric Rating Scale (NRS)
Phase I: Maximum Observed Peripheral Blood iNKT-Cell Concentration (Cmax)
Phase I: Time to Maximum Peripheral Blood iNKT-Cell Concentration (Tmax)
Phase I: Area Under the Concentration-Time Curve From Time Zero to the Last Quantifiable Time Point (AUC0-t)
Phase I: Area Under the Concentration-Time Curve From Time Zero to Infinity (AUC0-inf)
Phase I: Peripheral Immune-Cell Subsets Change From Baseline
Phase I: Plasma Cytokines and Other Soluble Biomarkers Change From Baseline
Phase II: Progression-Free Survival
Phase II: Objective Response Rate
Phase II: Disease Control Rate
Phase II: Duration of Response
Phase II: Time to Progression
Phase II: One-Year Overall Survival Rate
Phase II: Overall Survival
Phase II: Tumour Markers
Phase II:Quality of Life Change From Baseline Measured by European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Phase II: Pancreatic Cancer-Specific Quality of Life Change From Baseline Measured by the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Pancreatic Cancer Module 26 (EORTC QLQ-PAN26).
Phase II: Fatigue Change From Baseline Measured by the Brief Fatigue Inventory (BFI)
Phase II:Pain Change From Baseline Measured by the Numeric Rating Scale (NRS)
Phase II: Incidence and Severity of Adverse Events and Serious Adverse Events
Phase II: Maximum Observed Peripheral Blood iNKT-Cell Concentration (Cmax)
Phase II: Time to Maximum Peripheral Blood iNKT-Cell Concentration (Tmax)
Phase II: Area Under the Concentration-Time Curve From Time Zero to the Last Quantifiable Time Point (AUC0-t)
Phase II: Peripheral Immune-Cell Subsets Change From Baseline
Phase II: Plasma Cytokines and Other Soluble Biomarkers Change From Baseline

Arms and interventions

Phase I Low-Dose CohortExperimental

Low-Dose GKL-006 injection plus AG regimen

Phase I High-Dose CohortExperimental

High-Dose GKL-006 injection plus AG regimen

Phase II Investigational ArmExperimental

Selected dose level of GKL-006 injection from phase I plus AG regimen

Phase II Control ArmActive comparator

AG regimen, Nab-paclitaxel and gemcitabine per protocol

Biologicals: GKL-006 injection

Drugs: Nab-paclitaxel and Gemcitabine

Sites

1 site in 1 country

  • No. 1 Shuaifuyuan, Wangfujing, Dongcheng DistrictBeijing, Beijing Municipality, China